Yesterday, 3SBio shot 23% higher after an analyst for CIBC World Markets, predicted earnings for 3SBio would quadruple by 2009. As reason for the growth, the analyst cited great prospects for the company’s main revenue-producing drug, EPIAO, predicting also that 3SBio would climb to $17 per share.  3SBio responded by rising $2.70 to close at $14.35. More details...